Using Less Neurotoxic Drugs in Patients With HAND (MARAND-X)
Status:
Terminated
Trial end date:
2020-06-30
Target enrollment:
Participant gender:
Summary
Neurocognitive disorders are still highly prevalent in the HAART era; despite a dramatic
reduction in dementia cases, 15-50% of patients may develop mild or asymptomatic
neurocognitive disorders (HIV-associated neurocognitive disorders, HAND).
Among other hypothesis neurotoxicity of antiretrovirals has been postulated but its impact is
unknown.
Our hypothesis is that using drugs with reduced in vitro neurotoxicity may improve cognition
in HIV-positive patients withHAND.
76 patients with HAND will be randomized to either continue their treatment or switch to
emtricitabine, darunavir/cobicistat, maraviroc. Patients will be re-tested 6 months later.